<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0253-570X</journal-id>
<journal-title><![CDATA[Revista de Salud Animal]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Salud Anim.]]></abbrev-journal-title>
<issn>0253-570X</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Sanidad Agropecuaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0253-570X2008000100006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[PASO DE LA MOLÉCULA DE ERITROPOYETINA HUMANA RECOMBINANTE CON BAJO CONTENIDO DE ÁCIDO SIÁLICO AL SISTEMA NERVIOSO CENTRAL POR LA VÍA INTRANASAL EN LOS MODELOS DEL Meriones unguiculatus Y EL PRIMATE NO HUMANO Macaca fascicularis]]></article-title>
<article-title xml:lang="en"><![CDATA[RECOMBINANT HUMAN ERYTHROPOIETIN WITH LOW SIALIC ACID PATHWAY TO THE CENTRAL NERVOUS SISTEM BY INTRANASAL ROUTE IN Meriones unguiculatus AND NO HUMAN PRIMATE Macaca fascicularis MODELS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[Iliana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[Janette]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mengana]]></surname>
<given-names><![CDATA[Yuneidys]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Salman]]></surname>
<given-names><![CDATA[J.D]]></given-names>
</name>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="A05"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ozuna]]></surname>
<given-names><![CDATA[Tamara G]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J.C]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Nacional para la Producción de animales de Laboratorio  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A04">
<institution><![CDATA[,Instituto de Neurología y Neurocirugía  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Instituto Superior de Tecnología Aplicada  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Centro de Inmunología Molecular  ]]></institution>
<addr-line><![CDATA[Ciudad de la Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="A05">
<institution><![CDATA[,Centro de Investigación y Desarrollo de Medicamentos  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2008</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>39</fpage>
<lpage>44</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0253-570X2008000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0253-570X2008000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0253-570X2008000100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El objetivo de este estudio fue demostrar la llegada al cerebro de la molécula de eritropoyetina recombinante humana, con bajo contenido en ácidos siálicos, administrada por vía nasal en el gerbo de Mongolia y el primate Macaca fascicularis, así como la seguridad de aplicación nasal en ambas especies. Se emplearon 18 gerbos de Mongolia a los cuales se les administró eritropoyetina marcada con I125. La radioactividad asociada al bulbo olfatorio y al cerebelo fue determinada mediante un contador gamma. En un segundo experimento se administró eritropoyetina por vía nasal en 10 monos. El contenido de eritropoyetina en suero y líquido cefalorraquídeo obtenido por punción lumbar fue determinado por un ELISA que cuantifica la cantidad de molécula presente por mL. Se detectó un 0,8% de la radioactividad aplicada por la vía nasal, en el bulbo olfatorio, 5 min después de la aplicación en el gerbil de Mongolia. En el M. fascicularis se determinó un 0,15% de la dosis aplicada por vía nasal en el líquido cefalorraquídeo lumbar a los 15 min. No se observaron cambios en los parámetros sanguíneos en estas especies. Los resultados sugieren que la vía nasal constituye una alternativa de acceso no invasivo y seguro de la molécula de eritropoyetina humana recombinante al SNC, que puede tener uso como neuroprotector en accidentes cerebrovasculares, que constituyen en la actualidad un problema de salud humana.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Our propose was to demonstrate the brain access of the recombinant human erythropoietin, with low sialic acid content, in the Mongolian gerbil and Macaca fascicularis, as well as the safety of nasal administration in both species. Eighteen Mongolian gerbils received intranasally I125 labelled erythropoietin. Olfactory bulb and cerebellum-associated radioactivity were measured by a gamma counter. In a second experiment, erythropoietin was intranasally administered to 10 monkeys. Erythropoietin content in serum and cerebrospinal fluid obtained by lumbar puncture was determined by an ELISA method. From the intranasal administered radioactivity, a 0,8% was detected in the olfactory bulb at 5 min. In M. fascicularis, a 0,15% of the dose was determined in the cerebrospinal fluid 15 min after the intranasal administration. Treatment related-changes in blood parameters in both species were not observed. Results suggest that nasal route may be an alternative, non invasive and sure mode of access to the brain for the erythropoietin, which can be used as neuroprotector in stroke, a current health problem nowadays.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Eritropoyetina]]></kwd>
<kwd lng="es"><![CDATA[vía intranasal]]></kwd>
<kwd lng="es"><![CDATA[Macaca fascicularis]]></kwd>
<kwd lng="es"><![CDATA[cinética]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="es"><![CDATA[gerbo de Mongolia]]></kwd>
<kwd lng="es"><![CDATA[Meriones unguiculatus]]></kwd>
<kwd lng="en"><![CDATA[erythropoietin]]></kwd>
<kwd lng="en"><![CDATA[intranasal route]]></kwd>
<kwd lng="en"><![CDATA[Macaca fascicularis]]></kwd>
<kwd lng="en"><![CDATA[kinetics]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
<kwd lng="en"><![CDATA[Mongolian gerbil]]></kwd>
<kwd lng="en"><![CDATA[Meriones unguiculatus]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <div align="right">       <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Art&iacute;culo      rese&ntilde;a </b></font></p>       <p align="left"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">          <BR>     <b><font size="4">PASO DE LA MOL&Eacute;CULA DE ERITROPOYETINA HUMANA RECOMBINANTE      CON BAJO CONTENIDO DE &Aacute;CIDO SI&Aacute;LICO AL SISTEMA NERVIOSO CENTRAL      POR LA V&Iacute;A INTRANASAL EN LOS MODELOS DEL Meriones unguiculatus Y EL      PRIMATE NO HUMANO Macaca fascicularis</font></b> </font></p>       <p align="left">&nbsp;</p>       <p align="left"> <font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>RECOMBINANT      HUMAN ERYTHROPOIETIN WITH LOW SIALIC ACID PATHWAY TO THE CENTRAL NERVOUS SISTEM      BY INTRANASAL ROUTE IN Meriones unguiculatus AND NO HUMAN PRIMATE Macaca fascicularis      MODELS</b></font>       <p align="left">&nbsp; </p> </div>     <P>&nbsp;     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Iliana Sosa*,    Janette Cruz****,<SUP> </SUP>J. Santana***, Yuneidys Mengana*, J.D Garc&iacute;a-Salman<SUP>**</SUP>,    Adriana Mu&ntilde;oz*****, Tamara G. Ozuna* y J.C. Garc&iacute;a*</b></font>     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>*Centro Nacional    para la Producci&oacute;n de animales de Laboratorio, Bejucal, La Habana, Cuba.    Correo electr&oacute;nico: ccalidad@cenpalab.inf.cu, **Instituto de Neurolog&iacute;a    y Neurocirug&iacute;a, 29 y D, Vedado, Ciudad de La Habana, Cuba. ***Instituto    Superior de Tecnolog&iacute;a Aplicada, Ciudad de La Habana, Cuba. ****Centro    de Inmunolog&iacute;a Molecular, Ciudad de la Habana, Cuba. *****Centro de Investigaci&oacute;n    y Desarrollo de Medicamentos, Ciudad de La Habana, Cuba </i></font>     ]]></body>
<body><![CDATA[<P>&nbsp;     <P>&nbsp; <hr noshade size="1">     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font>     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2">El objetivo de    este estudio fue demostrar la llegada al cerebro de la mol&eacute;cula de eritropoyetina    recombinante humana, con bajo contenido en &aacute;cidos si&aacute;licos, administrada    por v&iacute;a nasal en el gerbo de Mongolia y el primate Macaca fascicularis,    as&iacute; como la seguridad de aplicaci&oacute;n nasal en ambas especies. Se    emplearon 18 gerbos de Mongolia a los cuales se les administr&oacute; eritropoyetina    marcada con I<SUP>125</SUP>. La radioactividad asociada al bulbo olfatorio y    al cerebelo fue determinada mediante un contador gamma. En un segundo experimento    se administr&oacute; eritropoyetina por v&iacute;a nasal en 10 monos. El contenido    de eritropoyetina en suero y l&iacute;quido cefalorraqu&iacute;deo obtenido    por punci&oacute;n lumbar fue determinado por un ELISA que cuantifica la cantidad    de mol&eacute;cula presente por mL. Se detect&oacute; un 0,8% de la radioactividad    aplicada por la v&iacute;a nasal, en el bulbo olfatorio, 5 min despu&eacute;s    de la aplicaci&oacute;n en el gerbil de Mongolia. En el M. fascicularis se determin&oacute;    un 0,15% de la dosis aplicada por v&iacute;a nasal en el l&iacute;quido cefalorraqu&iacute;deo    lumbar a los 15 min. No se observaron cambios en los par&aacute;metros sangu&iacute;neos    en estas especies. Los resultados sugieren que la v&iacute;a nasal constituye    una alternativa de acceso no invasivo y seguro de la mol&eacute;cula de eritropoyetina    humana recombinante al SNC, que puede tener uso como neuroprotector en accidentes    cerebrovasculares, que constituyen en la actualidad un problema de salud humana.    </font>     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palabras clave:</b>    Eritropoyetina; v&iacute;a intranasal; Macaca fascicularis; cin&eacute;tica;    seguridad; gerbo de Mongolia; Meriones unguiculatus</font> <hr>     <P>      <P><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">ABSTRACT</font></b>     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Our propose was    to demonstrate the brain access of the recombinant human erythropoietin, with    low sialic acid content, in the Mongolian gerbil and Macaca fascicularis, as    well as the safety of nasal administration in both species. Eighteen Mongolian    gerbils received intranasally I<SUP>125</SUP> labelled erythropoietin. Olfactory    bulb and cerebellum-associated radioactivity were measured by a gamma counter.    In a second experiment, erythropoietin was intranasally administered to 10 monkeys.    Erythropoietin content in serum and cerebrospinal fluid obtained by lumbar puncture    was determined by an ELISA method. From the intranasal administered radioactivity,    a 0,8% was detected in the olfactory bulb at 5 min. In M. fascicularis, a 0,15%    of the dose was determined in the cerebrospinal fluid 15 min after the intranasal    administration. Treatment related-changes in blood parameters in both species    were not observed. Results suggest that nasal route may be an alternative, non    invasive and sure mode of access to the brain for the erythropoietin, which    can be used as neuroprotector in stroke, a current health problem nowadays.    </font>     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Key words:</b>    erythropoietin; intranasal route; Macaca fascicularis; kinetics; safety; Mongolian    gerbil; Meriones unguiculatus</font> <hr noshade size="1">     <P><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Texto completo    en formato PDF    ]]></body>
<body><![CDATA[<BR>       <BR>   </font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alafaci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Salpietro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grasso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2000</year>
<volume>406</volume>
<page-range>219-225</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balin]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Broadwell]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Salcman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[El-Kolling]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Avenue for entry of peripherally administered protein in the central nervous system in mouse, rat and squirrel monkey]]></article-title>
<source><![CDATA[J Comp Neurol]]></source>
<year>1986</year>
<volume>251</volume>
<page-range>260-280</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banks]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Are the extracellular pathways a conduit for the delivery of therapeutics to the brain?]]></article-title>
<source><![CDATA[Current Pharmaceutical Design]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>1365-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becerra]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin-an endogenous retinal survival factor]]></article-title>
<source><![CDATA[Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<page-range>1968-1970</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bianchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Buyukakilli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brines]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin both protects from and reverses experimental diabetic neuropathy]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2004</year>
<volume>101</volume>
<page-range>823-828</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bohlius]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Langensiepen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schwarzer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2005</year>
<volume>97</volume>
<page-range>489-498</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bolton]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Radioiodination techniques]]></article-title>
<source><![CDATA[Amersham International Reviews]]></source>
<year>1985</year>
<volume>18</volume>
<page-range>13-17</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brines]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Ghezzi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Keenan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin crosses the blood brain barrier to protect against experimental brain injury]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2000</year>
<volume>97</volume>
<page-range>10526-31</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Mu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wendland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin improves functional and histological outcome in neonatal stroke]]></article-title>
<source><![CDATA[Pediatr Res]]></source>
<year>2005</year>
<volume>58</volume>
<page-range>106-111</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coscarella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liddi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zappitelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Urso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mele]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys]]></article-title>
<source><![CDATA[Mol Biotechnol]]></source>
<year>1998</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Degner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin: a candidate compound for neuroprotection in schizophrenia]]></article-title>
<source><![CDATA[Mol Psychiatry]]></source>
<year>2004</year>
<volume>9</volume>
<page-range>42-54</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diem]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sattler]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Merkler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2005</year>
<volume>128</volume>
<page-range>375-385</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Pardridge]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human blood-brain barrier insulin-like growth factor receptor]]></article-title>
<source><![CDATA[Metabolism]]></source>
<year>1988</year>
<volume>37</volume>
<page-range>136-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ehrenreich]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hasselblatt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dembowski]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin therapy for acute stroke is both safe and beneficial]]></article-title>
<source><![CDATA[Mol Med]]></source>
<year>2002</year>
<volume>8</volume>
<page-range>495-505</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fantacci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bianciardi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Caretti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Cerami]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brines]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia]]></article-title>
<source><![CDATA[PNAS]]></source>
<year>2006</year>
<volume>103</volume>
<numero>46</numero>
<issue>46</issue>
<page-range>17531-17536</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Thoner]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Fawcett]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ala]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Delivery of 125 I-NGF to the brain via the olfactory route]]></article-title>
<source><![CDATA[Drug Delivery]]></source>
<year>1997</year>
<volume>4</volume>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcma Salman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Protección neuronal endógena: un enfoque alternativo]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2004</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>150-155</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genc]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koroglu]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Genc]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin and the nervous system]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>2004</year>
<volume>1000</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>19-31</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Golden]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Maccagnan]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pardridge]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1997</year>
<volume>99</volume>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gokmen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Erbayraktar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2002</year>
<volume>99</volume>
<page-range>9450-9455</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graff]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Pollack]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nasal drug administration: potential for targeted central nervous system delivery]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>2005</year>
<volume>94</volume>
<page-range>1187-1195</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Swenberg]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fields]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Popp]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparative morphometry of the nasal cavity in rats and mice]]></article-title>
<source><![CDATA[J Anat]]></source>
<year>1982</year>
<volume>135</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hilger]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Applied anatomy and physiology of the nose]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Boies]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Hilger]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<source><![CDATA[Boies Fundamentals of Otolaryngology]]></source>
<year></year>
<edition>6th</edition>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Illum]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nasal drug delivery-possibilities, problems and solutions]]></article-title>
<source><![CDATA[J Control Release]]></source>
<year>2003</year>
<volume>87</volume>
<page-range>187-198</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelkmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular biology of erythropoietin]]></article-title>
<source><![CDATA[Intern Med]]></source>
<year>2004</year>
<volume>43</volume>
<page-range>649-659</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumral]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gonenc]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Acikgoz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats]]></article-title>
<source><![CDATA[Biol Neonate]]></source>
<year>2005</year>
<volume>87</volume>
<page-range>15-18</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lappin]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[EPO's Alter Ego: Erythropoietin Has Multiple Actions]]></article-title>
<source><![CDATA[Stem Cells]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>485-492</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beneficial effect of erythropoietin on experimental allergic encephalomyelitis]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2004</year>
<volume>56</volume>
<page-range>767-777</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin treatment improves neurological functional recovery in EAE mice]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>2005</year>
<volume>1034</volume>
<page-range>34-39</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipic]]></surname>
<given-names><![CDATA[Erik]]></given-names>
</name>
<name>
<surname><![CDATA[Schoemaker Regien]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[van der Meer]]></surname>
<given-names><![CDATA[Peter]]></given-names>
</name>
<name>
<surname><![CDATA[Voors Adriaan]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[Dirk]]></given-names>
</name>
<name>
<surname><![CDATA[van Gilst Wiek]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Protective effects of erythropoietin in cardiac ischemia: from bench to bedside]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmood]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury]]></article-title>
<source><![CDATA[J Neurotrauma.]]></source>
<year>2005</year>
<volume>22</volume>
<page-range>1011-1017</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masuda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Okano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamagishi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nagao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ueda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A novel site of erythropoietin production: Oxygen-dependent production in cultured rat astrocytes]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>1994</year>
<volume>269</volume>
<page-range>19488-19493</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Central nervous system frontiers for the use of erythropoietin]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2003</year>
<volume>37</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>S323</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization]]></article-title>
<source><![CDATA[Proc Natl Acad Sci]]></source>
<year>1986</year>
<volume>83</volume>
<page-range>6465-6469</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakane]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Akizuki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nadai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hashida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity]]></article-title>
<source><![CDATA[J Pharm Pharmacol]]></source>
<year>2000</year>
<volume>43</volume>
<page-range>449-451</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattler]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Merkler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Maier]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis]]></article-title>
<source><![CDATA[Cell Death]]></source>
<year>2004</year>
<volume>11</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S181-S192</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Erythropoietin has neuroprotective effects with functional recovery in experimental intracerebral hemorrhage: Annual Meeting of the American Academy of Neurology]]></source>
<year></year>
<edition>57</edition>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[TI]]></given-names>
</name>
<name>
<surname><![CDATA[García Rodríguez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Garcma Salman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Subirós]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils]]></article-title>
<source><![CDATA[Pharmacologyonline]]></source>
<year>2006</year>
<volume>1</volume>
<page-range>100-112</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Subiros]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[García Rodríguez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[TI]]></given-names>
</name>
<name>
<surname><![CDATA[Garcma Salman]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación histológica del efecto de la Eritropoyetina nasal sobre la muerte neuronal retardada en gerbos sometidos a isquemia cerebral transitoria: Estudio preliminar. Séptimo Congreso Virtual Hispanoamericano de Anatomía patológica y Primer Congreso de preparaciones virtuales por INTERNET]]></source>
<year>2005</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thorne]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Emory]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ala]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Quantitative analysis of the olfactory pathway for drug delivery to the brain]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>Sep </year>
<month>19</month>
<day>95</day>
<volume>186 92</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>278-82</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van der Meer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Voors Adriaan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lipsic]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[van Gilst Wiek]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen Dirk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin in cardiovascular diseases]]></article-title>
<source><![CDATA[European Heart Journal]]></source>
<year>2005</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>285-291</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gerwien]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Schrattenholz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sandberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>2004</year>
<volume>91</volume>
<page-range>900-910</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yatsiv]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Grigoriadis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Simeonidou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury]]></article-title>
<source><![CDATA[Faseb J]]></source>
<year>2005</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>179-186</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[QQ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[EQ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>2005</year>
<volume>387</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-10</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
